US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Weight Loss Drugs

1,257.83

+13.801.11%

Number of Gainers:6

Number of Losers:1

Number of Flat:- -

PE:- -

High:1,263.83

Open:1,245.45

Low:1,245.45

Close:1,244.03

Loading ...

Advisory: an Alert Tagged to Pfizer From a Law Firm Release Is Being Withdrawn

THOMSON REUTERS

Hearing Against Pfizer Set for 30 May in Contraceptive ‘Depo-Provera’ Multidistrict Litigation Overseen by Levin Papantonio

THOMSON REUTERS

Pfizer and BioNTech Submit EMA Application for COVID-19 Vaccine Targeting LP.8.1 for 2025-2026 Season

Acepodia Reaches Agreement With Pfizer to Terminate Cooperation in Autoimmune Diseases New Drugs Development

THOMSON REUTERS

BRIEF-Acepodia and Pfizer To Terminate Cooperation in Autoimmune Diseases Drugs Development

Avacta Group plc Appoints David Bryant and Richard Hughes as New Non-Executive Directors

Novo Nordisk's 52% Plunge: Is the Company Fumbling Its Leadership in the $150 Billion Weight Loss Market?

BeiGene Ltd. Announces Share Purchase Agreement with Amgen Inc

Viking Therapeutics Inc. Conducted Annual Stockholders Meeting

3 Surprising Stocks That Have More Than Doubled in 2025

Why Novo Nordisk Stock Just Popped

Is Pfizer Stock a Buy After This $1.25 Billion Investment?

Investors Heavily Search Amgen Inc. (AMGN): Here is What You Need to Know

Amgen Inc. Conducted Annual Meeting with Shareholders

Here's How the Pharmaceutical Import Tariffs Could Affect Eli Lilly

Analysts Have Conflicting Sentiments on These Healthcare Companies: Novo Nordisk (NVO), Beam Therapeutics (BEAM) and TScan Therapeutics (TCRX)

1 Ultra-High-Yield Dividend Stock Down 57% to Buy Hand Over Fist

U.S. Pharmaceutical Imports Might Soon Face Tariffs: 3 Stocks That Could Tumble as a Result

The New Covid-19 Jab Policy Wasn't Up for Debate at the FDA's Vaccine Meeting. Major Questions Remain. -- Barrons.com

Novo Nordisk Receives Positive Opinion From EU Committee on Extension of Saxenda Indication

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BK4599/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4599","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4599\",,,,,undefined,":{"symbol":"BK4599","market":"US","secType":"PLATE","nameCN":"Weight Loss Drugs","latestPrice":1257.8302,"timestamp":1749239999999,"preClose":1244.0306,"halted":0,"volume":51513461,"delay":0,"changeRate":0.011093,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Market Closed","change":13.799561,"latestTime":"06-06 16:00:00 EDT","open":1245.4493,"high":1263.8325,"low":1245.4493,"amount":3711906755.507839,"amplitude":0.014777,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1749456000000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":9.690713,"peRate":32.301623,"turnoverRate":0.004869,"increases":6,"decrements":1,"flats":0,"marketCap":1354591922304,"floatMarketCap":1258679594368},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4599\",,,,,undefined,":{"symbol":"BK4599","high":1263.8325,"amplitude":0.014777,"preClose":1244.0306,"low":1245.4493,"pbRate":"9.690713","latestPrice":1257.8302,"volume":51513461,"delay":0,"open":1245.4493,"prevYearClose":1305.0607,"prevWeekClose":1216.6,"prevMonthClose":1216.6,"prevQuarterClose":1314.3724,"fiveDayClose":1216.6,"twentyDayClose":1196.4727,"sixtyDayClose":1333.0085,"secType":"PLATE","market":"US","turnoverRate":0.004869,"peRate":32.301623,"marketCap":1354591922304,"floatMarketCap":1258679594368,"timestamp":1749239999999,"nameCN":"Weight Loss Drugs"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4599\",,,,undefined,":{"bkCode":"BK4599","up":6,"down":1,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4599\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2538880475","title":"Advisory: an Alert Tagged to Pfizer From a Law Firm Release Is Being Withdrawn","url":"https://stock-news.laohu8.com/highlight/detail?id=2538880475","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538880475?lang=en_us&edition=fundamental","pubTime":"2025-05-28 20:00","pubTimestamp":1748433601,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250528:nTUAMRJWW:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SG9999003800.SGD","LU0225284248.USD","SG9999011175.SGD","IE0002270589.USD","LU0985481810.HKD","SG9999001176.SGD","IE00BLSP4239.USD","SG9999013999.USD","IE00B19Z3581.USD","BK4550","LU0058720904.USD","LU0122379950.USD","LU0306807586.USD","LU0225771236.USD","SG9999002232.USD","LU1883839398.USD","SG9999001176.USD","LU1023059063.AUD","IE00BLSP4452.SGD","LU0321505439.SGD","LU1066051498.USD","LU0234572021.USD","LU0289739699.SGD","SGXZ57979304.SGD","LU1894683348.USD","BK4585","LU0306806265.USD","IE00BBT3K403.USD","PFE","BK4533","BK4592","LU0321505868.SGD","BK4568","BK4534","BK4599","LU0456855351.SGD","BK4007","LU1894683264.USD","LU1057294990.SGD","IE000M9KFDE8.USD","SG9999002224.SGD","IE00B19Z3B42.SGD","LU0868494617.USD","LU1066053197.SGD","LU0170899867.USD","BK4581","BK4588"],"gpt_icon":0},{"id":"2538473720","title":"Hearing Against Pfizer Set for 30 May in Contraceptive ‘Depo-Provera’ Multidistrict Litigation Overseen by Levin Papantonio","url":"https://stock-news.laohu8.com/highlight/detail?id=2538473720","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538473720?lang=en_us&edition=fundamental","pubTime":"2025-05-28 20:00","pubTimestamp":1748433601,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250528:nTUAMRJWW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1023059063.AUD","LU1883839398.USD","LU0306807586.USD","SG9999003800.SGD","BK4533","LU0306806265.USD","BK4585","IE0002270589.USD","LU0289739699.SGD","LU1066051498.USD","LU1066053197.SGD","LU1894683264.USD","LU0868494617.USD","IE00BLSP4239.USD","PFE","IE00BLSP4452.SGD","SG9999002232.USD","BK4534","SG9999001176.SGD","BK4599","SG9999013999.USD","IE000M9KFDE8.USD","LU0985481810.HKD","SG9999002224.SGD","IE00B19Z3B42.SGD","LU0321505868.SGD","LU0234572021.USD","SG9999001176.USD","BK4581","LU0170899867.USD","LU0456855351.SGD","LU0122379950.USD","BK4568","LU0225771236.USD","IE00B19Z3581.USD","BK4550","BK4588","SGXZ57979304.SGD","LU0321505439.SGD","BK4007","LU1894683348.USD","IE00BBT3K403.USD","LU1057294990.SGD","BK4592","SG9999011175.SGD","LU0058720904.USD","LU0225284248.USD"],"gpt_icon":0},{"id":"2538742054","title":"Pfizer and BioNTech Submit EMA Application for COVID-19 Vaccine Targeting LP.8.1 for 2025-2026 Season","url":"https://stock-news.laohu8.com/highlight/detail?id=2538742054","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538742054?lang=en_us&edition=fundamental","pubTime":"2025-05-28 18:58","pubTimestamp":1748429892,"startTime":"0","endTime":"0","summary":"Pfizer Inc. and BioNTech SE have submitted a regulatory application to the European Medicines Agency  for the approval of their COVID-19 vaccine, COMIRNATY, targeting the LP.8.1 strain for the 2025-2026 season. This submission follows the EMA's Emergency Task Force recommendation to update the vaccine composition to address the LP.8.1 strain. The vaccine, developed using BioNTech's proprietary mRNA technology, is aimed at enhancing protection against COVID-19 for individuals 12 years and older. The regulatory review is ongoing, and the companies are awaiting approval to proceed with distribution for the upcoming season.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pfizer Inc. published the original content used to generate this news ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250528:nNDL68xskw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0225771236.USD","LU0456855351.SGD","IE0002270589.USD","LU1894683348.USD","BNTX","BK4551","BK4535","LU1057294990.SGD","SGXZ57979304.SGD","BK4588","IE00B19Z3B42.SGD","SG9999013999.USD","BK4548","BK4550","LU0289739699.SGD","LU0234572021.USD","LU0321505439.SGD","PFE","SG9999001176.USD","BK4139","BK4534","SG9999003800.SGD","LU0306807586.USD","SG9999002232.USD","IE000M9KFDE8.USD","BK4581","IE00BLSP4239.USD","LU0225284248.USD","BK4599","BK4007","LU1023059063.AUD","LU0122379950.USD","LU0306806265.USD","LU0170899867.USD","IE00BLSP4452.SGD","LU0058720904.USD","BK4585","LU0321505868.SGD","BK4533","LU0985481810.HKD","BK4592","LU1066051498.USD","IE00BBT3K403.USD","LU1883839398.USD","SG9999001176.SGD","SG9999002224.SGD","LU1894683264.USD","LU0868494617.USD","LU1066053197.SGD","BK4568"],"gpt_icon":1},{"id":"2538429951","title":"Acepodia  Reaches Agreement With Pfizer to Terminate Cooperation in Autoimmune Diseases New Drugs Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2538429951","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538429951?lang=en_us&edition=fundamental","pubTime":"2025-05-28 17:29","pubTimestamp":1748424574,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250528:nL3N3S00MM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4533","BK4534","LU0289739699.SGD","LU0868494617.USD","IE00B19Z3B42.SGD","LU0321505439.SGD","BK4585","BK4581","LU0306806265.USD","SG9999001176.USD","BK4592","IE000M9KFDE8.USD","LU1066051498.USD","SG9999001176.SGD","IE00BLSP4239.USD","LU0306807586.USD","BK4568","SG9999002232.USD","SG9999013999.USD","LU1023059063.AUD","LU1057294990.SGD","IE00B19Z3581.USD","BK4550","BK4588","LU1066053197.SGD","LU0225771236.USD","SG9999003800.SGD","SG9999011175.SGD","LU0985481810.HKD","LU0225284248.USD","SG9999002224.SGD","LU1894683348.USD","BK4599","LU0170899867.USD","LU0321505868.SGD","LU1894683264.USD","LU0234572021.USD","PFE","LU0058720904.USD","IE0002270589.USD","SGXZ57979304.SGD","BK4007","LU1883839398.USD","IE00BBT3K403.USD","LU0456855351.SGD","LU0122379950.USD","IE00BLSP4452.SGD"],"gpt_icon":0},{"id":"2538299224","title":"BRIEF-Acepodia and Pfizer To Terminate Cooperation in Autoimmune Diseases Drugs Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2538299224","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538299224?lang=en_us&edition=fundamental","pubTime":"2025-05-28 17:29","pubTimestamp":1748424574,"startTime":"0","endTime":"0","summary":"BRIEF-Acepodia and Pfizer To Terminate Cooperation in Autoimmune Diseases Drugs Development May 28 (Reuters) - Acepodia Inc 6976.TWO:REACHES AGREEMENT WITH PFIZER PFE.N TO TERMINATE COOPERATION IN AUT","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250528:nL3N3S00MM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0225284248.USD","LU0868494617.USD","SG9999002224.SGD","SG9999013999.USD","LU0289739699.SGD","IE00BLSP4452.SGD","LU1894683348.USD","BK4599","LU0170899867.USD","LU0234572021.USD","SGXZ57979304.SGD","SG9999002232.USD","BK4592","IE00BBT3K403.USD","BK4550","IE00B19Z3B42.SGD","LU1894683264.USD","PFE","BK4588","LU0225771236.USD","LU0321505439.SGD","IE000M9KFDE8.USD","SG9999001176.USD","IE0002270589.USD","LU1023059063.AUD","SG9999001176.SGD","LU1057294990.SGD","LU0306806265.USD","LU1066053197.SGD","LU0058720904.USD","LU0985481810.HKD","IE00BLSP4239.USD","LU0321505868.SGD","BK4533","IE00B19Z3581.USD","LU0122379950.USD","BK4007","BK4581","LU0456855351.SGD","LU1066051498.USD","SG9999011175.SGD","LU1883839398.USD","BK4585","BK4534","SG9999003800.SGD","BK4568","LU0306807586.USD"],"gpt_icon":0},{"id":"2538241428","title":"Avacta Group plc Appoints David Bryant and Richard Hughes as New Non-Executive Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2538241428","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538241428?lang=en_us&edition=fundamental","pubTime":"2025-05-28 16:38","pubTimestamp":1748421516,"startTime":"0","endTime":"0","summary":"Avacta Group plc has announced the appointment of David Bryant and Richard Hughes as Non-Executive Directors, effective immediately. David Bryant brings over 35 years of experience in the pharmaceutical industry, with previous roles at GSK, Pfizer, and Clinigen Group. Richard Hughes has over 30 years of experience in UK capital markets, having been involved in corporate finance, IPOs, and M&A. The appointments are expected to enhance the Board's capabilities as the company focuses on advancing its preCISION platform.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avacta Group plc published the original content used to generate this news brief on May 28, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250528:nNDL5hbfMl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1894683264.USD","BK4592","BK5083","LU0306806265.USD","LU1023059063.AUD","SG9999002232.USD","LU0321505868.SGD","LU1057294990.SGD","LU0456855351.SGD","IE00B19Z3581.USD","SG9999001176.USD","SG9999013999.USD","BK4588","LU0225284248.USD","IE00BBT3K403.USD","BK4581","LU0225771236.USD","BK4550","LU0058720904.USD","BK4585","BK4599","AVCT.UK","BK4533","SG9999003800.SGD","LU0985481810.HKD","IE0002270589.USD","IE000M9KFDE8.USD","LU0170899867.USD","IE00BLSP4239.USD","LU0306807586.USD","SG9999001176.SGD","LU0289739699.SGD","IE00BLSP4452.SGD","LU1066053197.SGD","LU0321505439.SGD","SG9999011175.SGD","SGXZ57979304.SGD","SG9999002224.SGD","LU1894683348.USD","LU1883839398.USD","LU0868494617.USD","BK4568","IE00B19Z3B42.SGD","BK4007","LU0234572021.USD","LU1066051498.USD","BK4534","LU0122379950.USD"],"gpt_icon":1},{"id":"2538842834","title":"Novo Nordisk's 52% Plunge: Is the Company Fumbling Its Leadership in the $150 Billion Weight Loss Market?","url":"https://stock-news.laohu8.com/highlight/detail?id=2538842834","media":"Motley Fool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538842834?lang=en_us&edition=fundamental","pubTime":"2025-05-28 16:15","pubTimestamp":1748420100,"startTime":"0","endTime":"0","summary":"Ozempic helped Novo Nordisk gain an early lead in the weight loss industry, but competition is nipping at the company's heels.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/investing/2025/05/28/novo-nordisk-53-plunge-is-the-company-fumbling-it/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["LU1093756168.USD","BK4599","LU2089283258.USD","LU0154236417.USD","LU2089284900.SGD","LU0314104364.USD","LU1162221912.USD","LU0912757837.SGD","LU2133065610.SGD","NVO","LU0795875169.SGD","LU0795875086.SGD","IE00BZ1G4Q59.USD","LU1074936037.SGD","LU1720051108.HKD","LU2028103732.USD","LU2357305700.SGD","BK4534","LU0971096721.USD","BK4007","LU0320765646.SGD","LU2023251221.USD","LU0106831901.USD","BK4588","LU1989772840.SGD","BK4127","LU1989772923.USD","BK4585","BK4516","LU0098860793.USD","LU1668664300.SGD","LU2347655156.SGD","LU1363072403.SGD","LU0267386448.USD","LU0158827948.USD","BK4532","LU0106261372.USD","LU0006306889.USD","LU1093756325.SGD","LU1548497426.USD","LU2271345857.HKD","IE00BKVL7J92.USD","BK4581","LU0158827781.USD","LU1732799900.SGD","LU0225283273.USD","LU1720051017.SGD","BK4504","LU2111349929.HKD","LU1732800096.USD"],"gpt_icon":1},{"id":"2538185774","title":"BeiGene Ltd. Announces Share Purchase Agreement with Amgen Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2538185774","media":"Reuters","labels":["shareholding","corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538185774?lang=en_us&edition=fundamental","pubTime":"2025-05-28 07:41","pubTimestamp":1748389267,"startTime":"0","endTime":"0","summary":"BeiGene Ltd. announced a significant development with the signing of a Share Purchase Agreement with Amgen Inc. on October 31, 2019. This agreement marks a strategic collaboration between the two companies, aiming to enhance their positions within the biopharmaceutical industry. An amendment to this agreement was made on December 6, 2019, highlighting ongoing negotiations and adjustments to optimize the partnership's outcomes. This collaboration is expected to drive innovation and expand market reach for both entities.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BeiGene Ltd. published the original content used to generate this news brief on May 28, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250527:nNDLc71DBb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1061106388.HKD","LU0058720904.USD","LU1571399168.USD","LU2112291526.USD","BK4534","IE00B2B36J28.USD","LU0320765992.SGD","BK4139","LU1023059063.AUD","BK4585","LU0868494617.USD","LU0109394709.USD","BK4533","688235","IE0009355771.USD","SG9999001440.SGD","LU0889565916.HKD","LU0289739699.SGD","IE00B4R5TH58.HKD","LU2242646821.SGD","IE00BFTCPJ56.SGD","BK4581","LU1983299246.USD","IE00BJT1NW94.SGD","LU2089984988.USD","BK0239","BK4599","IE0002141913.USD","LU2468319806.SGD","BK4588","AMGN","LU1057294990.SGD","LU0122379950.USD","BK4566","IE00BJJMRZ35.SGD","LU2242652126.USD"],"gpt_icon":0},{"id":"2538217492","title":"Viking Therapeutics Inc. Conducted Annual Stockholders Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2538217492","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538217492?lang=en_us&edition=fundamental","pubTime":"2025-05-28 05:20","pubTimestamp":1748380834,"startTime":"0","endTime":"0","summary":"Viking Therapeutics, Inc. held its 2025 Annual Meeting of Stockholders on May 20, 2025. Stockholders voted to elect Matthew W. Foehr and Charles A. Rowland, Jr. as Class I directors. The selection of CBIZ CPAs P.C. as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified. The compensation of the named executive officers was approved on an advisory basis.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Viking Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 27, 2025, and is solely responsible for the information con","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250527:nNDL7HHW7R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4585","BK4599","VKTX","BK4588"],"gpt_icon":0},{"id":"2538349840","title":"3 Surprising Stocks That Have More Than Doubled in 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2538349840","media":"Motley Fool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538349840?lang=en_us&edition=fundamental","pubTime":"2025-05-27 23:37","pubTimestamp":1748360220,"startTime":"0","endTime":"0","summary":"Just 14 stocks with market caps above $1 billion have doubled so far this year. They probably aren't the winners you would have predicted.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/investing/2025/05/27/3-surprising-stocks-that-have-more-than-doubled-in/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["LU1894683348.USD","LU0786609619.USD","BK4550","LU0154236417.USD","SG9999015952.SGD","LU1267930573.SGD","BK4108","SG9999015945.SGD","BK4598","BK4007","LU0011850046.USD","LU0061475181.USD","LU1093756325.SGD","LU0310800379.SGD","IE0002270589.USD","SG9999015986.USD","DIS","LU0208291251.USD","IE00B19Z3581.USD","IE00BKVL7J92.USD","LU0048573561.USD","BK4532","BK4585","LU0742534661.SGD","IE00B19Z3B42.SGD","IE00BZ1G4Q59.USD","BK4534","LU0029864427.USD","BK4581","BK4599","LU0640476718.USD","LU1894683264.USD","BK4551","LU0708994859.HKD","LU0251142724.SGD","BK4561","BK4588","BK4507","BK4554","BK4524","LU0128525929.USD","LU0251131958.USD","LU0070302665.USD","GB00BDT5M118.USD","LU0320765489.SGD","LU1280957306.USD","LU1093756168.USD","SG9999015978.USD"],"gpt_icon":1},{"id":"2538467739","title":"Why Novo Nordisk Stock Just Popped","url":"https://stock-news.laohu8.com/highlight/detail?id=2538467739","media":"Motley Fool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538467739?lang=en_us&edition=fundamental","pubTime":"2025-05-27 22:36","pubTimestamp":1748356560,"startTime":"0","endTime":"0","summary":"President Trump has good news for Novo Nordisk investors, and more may be on the way.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/investing/2025/05/27/why-novo-nordisk-stock-just-popped/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["IE00BZ1G4Q59.USD","BK4588","IE00BKVL7J92.USD","BK4585","BK4532","LU0154236417.USD","NVO","LU1093756168.USD","BK4599","LU1093756325.SGD","BK4007"],"gpt_icon":1},{"id":"2538404462","title":"Is Pfizer Stock a Buy After This $1.25 Billion Investment?","url":"https://stock-news.laohu8.com/highlight/detail?id=2538404462","media":"Motley Fool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538404462?lang=en_us&edition=fundamental","pubTime":"2025-05-27 22:00","pubTimestamp":1748354400,"startTime":"0","endTime":"0","summary":"Pfizer is licensing a promising investigational cancer medicine from a smaller company.This move improves the drugmaker's already attractive oncology pipeline.Pfizer  made a fortune thanks to its work in the COVID-19 market. In 2022, it became the first company in the biopharmaceutical industry to generate $100 billion in annual sales.However, the pandemic receded, and revenue in this area dropped off a cliff. The drugmaker has been looking for a way back ever since -- a product, or several, that can rack up billions in annual sales and help its top line move consistently in the right direction.It recently found a candidate for that position. Let's look deeper, and discuss whether the recent development makes Pfizer stock a buy.Image source: Getty Images.Entering a promising marketOn May. 19, Pfizer announced it was entering into a licensing agreement with 3SBio, a China-based biotech company. Per the terms of the deal, Pfizer will acquire the rights to develop and market SSGJ-707 -- a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/investing/2025/05/27/is-pfizer-stock-a-buy-after-125-billion-investment/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["BK4568","BK4588","IE0002270589.USD","SG9999011175.SGD","LU1894683348.USD","SG9999001176.SGD","LU0321505439.SGD","LU0234572021.USD","LU0985481810.HKD","BK4534","BK4550","IE000M9KFDE8.USD","LU0225284248.USD","LU1066053197.SGD","SGXZ57979304.SGD","PFE","BK4585","LU0289739699.SGD","LU1057294990.SGD","SG9999002232.USD","BK4007","LU1066051498.USD","LU0225771236.USD","LU0456855351.SGD","LU0122379950.USD","BK4581","LU1894683264.USD","SG9999013999.USD","SG9999001176.USD","LU0306806265.USD","LU0058720904.USD","IE00B19Z3581.USD","BK4599","LU0868494617.USD","LU1883839398.USD","SG9999003800.SGD","LU0170899867.USD","SG9999002224.SGD","IE00BLSP4239.USD","IE00BBT3K403.USD","BK4533","LU0321505868.SGD","LU0306807586.USD","LU1023059063.AUD","IE00BLSP4452.SGD","IE00B19Z3B42.SGD","BK4592"],"gpt_icon":1},{"id":"2539407501","title":"Investors Heavily Search Amgen Inc. (AMGN): Here is What You Need to Know","url":"https://stock-news.laohu8.com/highlight/detail?id=2539407501","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539407501?lang=en_us&edition=fundamental","pubTime":"2025-05-27 21:00","pubTimestamp":1748350809,"startTime":"0","endTime":"0","summary":"Amgen  has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.Shares of this world's largest biotech drugmaker have returned -4% over the past month versus the Zacks S&P 500 composite's +5.2% change. The Zacks Medical - Biomedical and Genetics industry, to which Amgen belongs, has lost 0.6% over this period. Now the key question is: Where could the stock be headed in the near term?While media releases or rumors about a substantial change in a company's business prospects usually make its stock 'trending' and lead to an immediate price change, there are always some fundamental facts that eventually dominate the buy-and-hold decision-making.While earnings growth is arguably the most superior indicator of a company's financial health, nothing happens as such if a business isn't able to grow its revenues. After all, it's nearly impossible for a company to increase its earnin","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/investors-heavily-search-amgen-inc-130009881.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1983299246.USD","LU2242652126.USD","LU0122379950.USD","SG9999001440.SGD","LU0868494617.USD","IE0002141913.USD","LU1023059063.AUD","BK4534","LU2242646821.SGD","IE00B4R5TH58.HKD","LU0320765992.SGD","LU0109394709.USD","LU2089984988.USD","AMGN","IE0009355771.USD","BK4585","BK4139","ISBC","BK4581","BK4588","BK4599","LU0058720904.USD","BK4566","LU1057294990.SGD","IE00B2B36J28.USD","LU2112291526.USD","LU0889565916.HKD","LU0289739699.SGD","IE00BJJMRZ35.SGD","BK4211","IE00BJT1NW94.SGD","BK4533","LU1061106388.HKD","LU1571399168.USD","LU2468319806.SGD","IE00BFTCPJ56.SGD"],"gpt_icon":0},{"id":"2538457936","title":"Amgen Inc. Conducted Annual Meeting with Shareholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2538457936","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538457936?lang=en_us&edition=fundamental","pubTime":"2025-05-27 18:01","pubTimestamp":1748340078,"startTime":"0","endTime":"0","summary":"Amgen Inc. held its Annual Meeting on May 23, 2025. The stockholders approved the election of board members and ratified the appointment of the independent registered public accounting firm. Additionally, a proposal regarding an amendment to the company's certificate of incorporation was approved. However, a stockholder proposal related to environmental sustainability was not approved.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amgen Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 27, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250527:nNDL463gJJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1023059063.AUD","LU0320765992.SGD","LU0889565916.HKD","LU2468319806.SGD","AMGN","IE00BFTCPJ56.SGD","LU2089984988.USD","BK4533","IE00BJT1NW94.SGD","BK4566","BK4585","LU1061106388.HKD","IE00B2B36J28.USD","LU0289739699.SGD","LU0868494617.USD","IE00B4R5TH58.HKD","LU0109394709.USD","BK4534","BK4599","LU1571399168.USD","LU1983299246.USD","SG9999001440.SGD","BK4581","IE0002141913.USD","LU2242652126.USD","LU0122379950.USD","IE00BJJMRZ35.SGD","IE0009355771.USD","LU2242646821.SGD","LU2112291526.USD","BK4588","BK4139","LU1057294990.SGD","LU0058720904.USD"],"gpt_icon":0},{"id":"2538145593","title":"Here's How the Pharmaceutical Import Tariffs Could Affect Eli Lilly","url":"https://stock-news.laohu8.com/highlight/detail?id=2538145593","media":"Motley Fool","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538145593?lang=en_us&edition=fundamental","pubTime":"2025-05-27 16:44","pubTimestamp":1748335440,"startTime":"0","endTime":"0","summary":"Tariffs on pharmaceutical imports could hurt Lilly, especially with its dependence on products made in Ireland.However, Lilly might not feel much pain if the Trump administration gives enough time for drugmakers to boost U.S. manufacturing.The president's most favored nation drug pricing could also be problematic for Lilly, but perhaps not as much as feared.Eli Lilly's  share price soared during the first Trump administration. That momentum continued with Joe Biden in the White House. However, it's a much different story so far in Trump's second term. The big pharma stock has taken investors on a roller coaster ride that's on a downward swing right now.Why has Lilly's stock been so volatile?The tariffs on pharmaceutical imports threatened by President Trump stand out as one key factor. Here's how those tariffs could affect Eli Lilly.Lilly's  luck of the Irish?","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/investing/2025/05/27/heres-how-the-pharmaceutical-import-tariffs-could/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["LU1551013425.SGD","IE00BJJMRZ35.SGD","BK4599","LU0689472784.USD","BK4516","LU0786609619.USD","LU0256863902.USD","LU1291159041.SGD","SG9999017495.SGD","BK4534","LU2063271972.USD","LU2106854487.HKD","LU2361044949.HKD","SG9999015978.USD","BK4588","LU0114720955.EUR","LU2112291526.USD","LU2237443978.SGD","IE00B4R5TH58.HKD","LU0640476718.USD","LU0417517546.SGD","IE00BFTCPJ56.SGD","LU1023059063.AUD","LU2361044865.SGD","IE00BJT1NW94.SGD","IE0009355771.USD","LU0354030438.USD","LU0320765992.SGD","LU1548497426.USD","LU2361045086.USD","BK4503","LLY","LU0198837287.USD","LU2324357040.USD","LU1804176565.USD","LU0672654240.SGD","SG9999015952.SGD","LU2491050154.USD","BK4007","LU1989771016.USD","API","LU0203201768.USD","LU0323591593.USD","LU0109394709.USD","LU2461242641.AUD","LU1720051108.HKD","LU2237443549.SGD","SG9999001176.SGD","LU1551013342.USD","LU0079474960.USD"],"gpt_icon":1},{"id":"2538111769","title":"Analysts Have Conflicting Sentiments on These Healthcare Companies: Novo Nordisk (NVO), Beam Therapeutics (BEAM) and TScan Therapeutics (TCRX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2538111769","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538111769?lang=en_us&edition=fundamental","pubTime":"2025-05-25 17:03","pubTimestamp":1748163782,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Novo Nordisk (NVO – Research Report), Beam Therape...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-novo-nordisk-nvo-beam-therapeutics-beam-and-tscan-therapeutics-tcrx?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-novo-nordisk-nvo-beam-therapeutics-beam-and-tscan-therapeutics-tcrx?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0154236417.USD","BK4599","BK4539","NVO","HCSG","BK4556","BK4007","IE00BKVL7J92.USD","BEAM","BK4137","BK4532","BK4585","BK4535","TCRX","IE00BZ1G4Q59.USD","BK4505","BK4611","BK4588","LU1093756168.USD","BK4139","LU1093756325.SGD"],"gpt_icon":0},{"id":"2537198381","title":"1 Ultra-High-Yield Dividend Stock Down 57% to Buy Hand Over Fist","url":"https://stock-news.laohu8.com/highlight/detail?id=2537198381","media":"Motley Fool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537198381?lang=en_us&edition=fundamental","pubTime":"2025-05-24 16:51","pubTimestamp":1748076660,"startTime":"0","endTime":"0","summary":"Pfizer faces several challenges, including looming patent expirations.However, the drugmaker's story is better than meets the eye.Pfizer's attractive valuation and ultra-high dividend yield make it a great pick right now.Most people like to buy products when prices are cheaper. That's why you'll probably see lots of car dealers, furniture stores, and retailers advertising special sales during the Memorial Day weekend.However, many investors are leery of buying a stock that has fallen sharply. Why?For one thing, Pfizer isn't nearly as reliant on COVID-19 product sales as it was during the peak of the pandemic. In the first quarter of 2025, COVID-19 vaccine Comirnaty and antiviral therapy P","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/investing/2025/05/24/1-ultra-high-yield-dividend-stock-down-57-to-buy-h/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["LU1023059063.AUD","LU1883839398.USD","US10Y.BOND","LU0306807586.USD","SG9999003800.SGD","US7Y.BOND","BK4533","IE00BMG7P694.USD","BK4585","IE0002270589.USD","US30Y.BOND","IE00BMG7P926.USD","LU0289739699.SGD","IE00BD4GTV84.USD","LU1066051498.USD","LU1066053197.SGD","US5Y.BOND","LU1894683264.USD","US3Y.BOND","IE00BLSP4239.USD","PFE","IE00BLSP4452.SGD","BK4534","SG9999001176.SGD","BK4599","SG9999013999.USD","LU0985481810.HKD","IE00B19Z3B42.SGD","LU0321505868.SGD","LU0234572021.USD","BK4581","LU0170899867.USD","PEG","LU0456855351.SGD","LU0122379950.USD","BK4568","US6M.BOND","US2Y.BOND","IE00B19Z3581.USD","BK4550","BK4588","US12M.BOND","SGXZ57979304.SGD","BK4007","LU1894683348.USD","BK4208","SG9999011175.SGD","LU1057294990.SGD","BK4592","IE00BD4GTW91.USD"],"gpt_icon":1},{"id":"2537160165","title":"U.S. Pharmaceutical Imports Might Soon Face Tariffs: 3 Stocks That Could Tumble as a Result","url":"https://stock-news.laohu8.com/highlight/detail?id=2537160165","media":"Motley Fool","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537160165?lang=en_us&edition=fundamental","pubTime":"2025-05-24 16:11","pubTimestamp":1748074260,"startTime":"0","endTime":"0","summary":"There's little doubt these pharmaceutical companies' costs will soon be rising at least a little.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/investing/2025/05/24/us-pharmaceutical-imports-tariffs-stocks/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["LU0321505868.SGD","SG9999002232.USD","LU0985481810.HKD","IE00B19Z3B42.SGD","SG9999002224.SGD","BK4007","PFE","IE00B19Z3581.USD","LU1066053197.SGD","SG9999001176.SGD","LU0122379950.USD","BK4533","LU0225284248.USD","LU0289739699.SGD","BK4550","LU1894683264.USD","BK4599","SG9999001176.USD","SG9999013999.USD","LU0225771236.USD","LU0306807586.USD","LU0456855351.SGD","IE0002270589.USD","LU0170899867.USD","LU0306806265.USD","LU0868494617.USD","LU1023059063.AUD","SGXZ57979304.SGD","LU1066051498.USD","LU1894683348.USD","LU1057294990.SGD","BK4592","BK4568","LU1883839398.USD","BK4588","BK4534","BK4585","LU0058720904.USD","LU0234572021.USD","IE00BLSP4239.USD","IE00BLSP4452.SGD","IE000M9KFDE8.USD","LU0321505439.SGD","SG9999011175.SGD","BK4581","IE00BBT3K403.USD","SG9999003800.SGD"],"gpt_icon":1},{"id":"2537517156","title":"The New Covid-19 Jab Policy Wasn't Up for Debate at the FDA's Vaccine Meeting. Major Questions Remain. -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2537517156","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537517156?lang=en_us&edition=fundamental","pubTime":"2025-05-24 01:16","pubTimestamp":1748020560,"startTime":"0","endTime":"0","summary":"The biggest news in U.S. vaccine policy wasn't up for discussion at Thursday's public meeting of the Food and Drug Administration's external vaccine advisory committee.Two days earlier, FDA Commissioner Dr. Marty Makary and his new top vaccine regulator, Dr. Vinay Prasad, had noisily announced a big change to how the agency approaches Covid-19 boosters. The FDA will still approve new updated shots for seniors and for high-risk adults, the agency leaders said, but will need new randomized, controlled trials to approve new shots for young and healthy adults.Regulators had already been leaning toward narrowing the rollout of this year's updated Covid-19 vaccine anyway, after recommending the shot for virtually everyone last year.There were basic questions about how the FDA's decision interacted with the new framework, however, that went unanswered at the meeting. When committee members asked if companies would need to run new randomized clinical trials if this year's shots targeted a diff","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","LU0306806265.USD","IE00BFXG1179.USD","SG9999002232.USD","LU1057294990.SGD","BK4007","BNTX","SG9999011175.SGD","IE0002270589.USD","IE00BBT3K403.USD","BK4588","BK4533","LU0170899867.USD","LU0122379950.USD","PFE","BK4581","LU0234572021.USD","SG9999003800.SGD","LU0225771236.USD","IE000M9KFDE8.USD","IE00B19Z3581.USD","BK4550","LU0289739699.SGD","LU0985481810.HKD","LU1894683264.USD","LU1066053197.SGD","SG9999002224.SGD","LU0456855351.SGD","IE00B19Z3B42.SGD","BK4585","BK4599","BK4568","LU0868494617.USD","LU1883839398.USD","SG9999001176.USD","BK4139","BK4592","LU0306807586.USD","LU1894683348.USD","LU1066051498.USD","LU1023059063.AUD","LU0321505868.SGD","BK4501","NVAX","IE00BLSP4239.USD","LU0058720904.USD","SNY","BK4551","SG9999013999.USD","MRNA"],"gpt_icon":1},{"id":"2537413243","title":"Novo Nordisk Receives Positive Opinion From EU Committee on Extension of Saxenda Indication","url":"https://stock-news.laohu8.com/highlight/detail?id=2537413243","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537413243?lang=en_us&edition=fundamental","pubTime":"2025-05-23 21:54","pubTimestamp":1748008461,"startTime":"0","endTime":"0","summary":"Novo Nordisk  has received the recommendation of the European Medicines Agency's Committee for Medicinal Products for Human Use for the extension of the current indication for Saxenda, according to a Friday statement from the regulator.The update in Saxenda's marketing authorization, once approved, will include the treatment of children aged 6 years to less than 12 years, the EMA said.Saxenda is currently indicated as an \"adjunct to healthy nutrition and increased physical activity for weight management,\" according to the statement.Price: 67.52, Change: -0.65, Percent Change: -0.95","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1093756168.USD","BK4007","BK7104","BK4156","BK4588","IE00BZ1G4Q59.USD","LU0154236417.USD","NVO","BK4599","BK4532","NVO.AU","BK4585","LU1093756325.SGD","IE00BKVL7J92.USD"],"gpt_icon":1}],"pageSize":20,"totalPage":5,"pageCount":4,"totalSize":82,"code":"91000000","status":"200"}]}}